Low -dose histamine therapy has been prescribed by otolary ngologists primarily to treat Bell's palsy, vestibular disorders, vascular headache, Meniere 's attacks, and urtica ria vasculitis. The scientific exp lanations for the usefuln ess of this once -empiric treatm ent are becomin g more apparent. Two methods of establishing the appropriate dosages have emerged: the empi ric, optimumdosage approa ch and the objective, endpoint-titration approach.
Introduction
Low-dose histamine therapy has been used success fully by otol aryngologist s for more than 50 yea rs. It has been especially use ful in treating patients with different form s of vasculitis, such as inner ear vestibular disorde rs, vascular headaches, and urticaria. Although its early use was largely empiric, its mechanisms of action are becoming more clear. With thi s enhanced understanding, othe r uses for low-dose histamine therapy are emerging.
Histamine is composed of an imidazole ring and an amino group connected by a short chain of two carb on atoms.' It is a decarboxylation product of the amino acid histidine. It is the primary toxin rele ased from basophils and tissue mast cells during an allergic reaction . Th ere are four other causes ofhistamine release : 1) a reaction to certain drugs, peptide s, venom, and other "liberators" ; 2) a physical insult (thermal, vibr atory, radiant, or exertional); 3) stress (chemical, traumatic, or osmoti c); and 4) spontaneous basophil release, wh ich is higher in atopic individuals .i"
Normal histamine blood levels range from 300 to 500 pg/ml. A level of several ng/ml would result in histamine shock .' Histamine' s phy siologic actions are medi ated by From 6 Th e H 3 receptors help regul ate the synthesis and rele ase of histamine from central ner vou s system histaminergic nerve endings.
Mechanisms of action
Early studies provided clues to the probable reason for the usefulness of histamine as a therapeutic agent. In 1922, Cooke illu strated how increasing doses of histamine delivered to a single puncture site resulted in fewer skin reactions, with toleranc e lasting at least 48 hours.' In 1936, Karady reported that guinea pig s that had been sensitized to egg albumin who were inje cted daily with hist amine had milder reactions than a control group when they were all reinj ec ted with egg albumin. " In 1939, Fa rmer observed an increased refractoriness of horseserum-sen sitiz ed guinea-pig uterine strips after histamine injection." In 1971 , Cir stea , recognizing an app arent therapeutic value of histamine, illustrated how this benefit was not the result of tachyphylaxis or the formation of antihistamine antibodies capabl e of neutralizing histamine.' ? Th at same year, Bourne et al reported that exogenous histamine ca used a dose-dependent inhibition of antigenic histamine rele ase from the cell s of atopic donors by stimulating cyclic AMP synthesis, I' a finding he and coll eagues empha sized again in 1975. 12 • 13 By 1979, histamine' s antiallergic affect s were wid ely recognized, and Gir sh ju stifi ably lamented the then-popular practice of using histamine placebo in double-blind studies of allergy treatment."
It is feasible that histamin e' s anti allergic effect is the collective result of the parad oxic al stimulation of peripheral microvascular dilation , synthesis of cyclic AMP, reduction of the inflammatory response , and activation of T suppressor cells.Moreover, the author believes that a synthesis of cyclic AMP may also be a result of low-dose histamine neutralization release of prostaglandin E series.'>"
Clinical uses for both approaches Empiric optimum-dose approach. Alfody " in 1938 chronicled the therapeutic usefulness of high-dose histamine therap y for the treatment of ves tibular diso rders, as ENT·Ear, Nose & Throat Journal" May 1999 (budesonide) Nasallnhaler
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DOSAGE AND ADMINISTRATION
Adultsand children6 years Df age and older: TherecDmmended st arlingdDse is 256pg daily, gi ven as either twD sprays ineach nDstril mDrning and evenin gDr asfDur sprays ineach nDstril in the morning. Adecrease in symptDms may Dccur as SODn as 24hDursall er Dnsel Df treatment wi thRhinD cDrl Nasal Inhaler but generally it takes3-7days tD reach maximum benefit. li nDimprD vementhas beenDbtainedbythethirdweekDt treatment wi thRhinDcDrtNasal Inhaler,trealment ShDUld bediscDntinued. Allerthe desiredclinical ellect has been Dbtained, themaintenance dDse ShDUldbereducedtD thesmallest amDunt necessary fDr cDntrol Dt symptDms. IIglucDcDrticDslerDids arediscDntinuedwhen they sti ll are needed, symptDms maynDt recur IDr several days. AIrecDmmended dDses, RhinDcDrt's Iherapeutic ellects areIDcalized to thenDse, therelDre, cDncDmitant treatment may be necessary tDCDunteract all er gic eye symptDms. DDses exceeding 256 pg daily (4 sprays/nDstril) are nDt rec Dmmended . RhinDcDrl Nasal Inhaler is nDt recDmmendedIDr child ren belDw6years D I ag eor fDr chi ldren wit hnDnallergicpe re nnial rhinitisbecauseadequate numbersDf thesechil dren havenDt been sludied. In 1950, Shambaugh reported on the success ful use of low-dose histamine treatment for histamin ic cephalalgia, Bell' s palsy, and postfenestration Meniere' s disease, and for attacks of Meniere' s disease. 18 Hansel and Anderson sugges ted the use of low-dose histamine for vascular headache and for auditory phenomen a such as vertigo, tinnitus, deafness, and Bell ' s palsy. 22 Clemis and McBrien also reported success with this techniqu e for patie nts with cochleovestibular disorders, and tinnitus. 23 ,24 The treatment techniqu e sugges ted by these authors is an empiric, optimum-dose approach wherei n subcutaneous injections of dilute histamine are administered once · or twice a week to initiate treatment and are supplemented by daily sublingual drops. The strength of the dose is increased to the point of optimum clinical response, but short of aggrava tion.
Objective endpoint-titration approach. The technique advoc ated by Wilson" and Powers" determin es subcutaneous and supplemental sublingual histamine doses by endpoint titration. A concentrate of 2.75 mg/ml of histamine phosphate is used to make fivefold dilution s, as per the system developed by Rinkel." Startin g with a #7 dilu tion, consecutively stronger 4mm intrac utaneo us bolu ses are administered at l Ovminute intervals until one of them causes a wheal that is 2 mm larger in width and height than the previous wheal, or the average of its width and height is 2 mm greater than the previous wheal. This is the dilution that will serve as the treatment dilution. If the treat ment dilution is weak er than #3, itshould be confirmed with another administration one dilution stronger. This additional administration should result in a wheal that is 2 mm larger than the wheal induc ed by the treatment dilution. If the skin does not respo nd to a #3 diluti on, the test is considere d to be nonreactive because of a medication or medical immunodeficiency, and thus is not reliable.
In this office, the objective endpoint-titration techn ique is preferred. The endpoint dose most freq uently identified is the #4 dilution, followed by #5 . The #3 and #6 diluti ons are rare ly identified. Never is a dilution stronger than #3 used for testing or treatment. A dose of 0.1 ml of the endpoint diluti on is used for treatment, both subcutaneously and sublingually. For comparison purp oses between different dilutions, it should be noted that 1 ml of the 2.75 mg/ml concentration of histamine pho sphate contains the equiva lent of 1 ml of a l : l ,OOO histamine base. The Hansel dilu tion system uses tenfold rather than Volume 78, Number 5 fivefold diluti ons; therefore, the Hansel system identifies the l : l ,OOO dilution as a #3 diluti on (table 2) .
Hansel sugges ted starting with the #7 dilution for dosage esca lation, which is roughly equivalent to a #5 . 5 Rinkel dilution." Shambaugh suggested starting with a Hansel #8 dilution, which is roughl y equivalent to a #7 Rinkel dilution." Thu s, while both techn iques ultimately determined approximately the same treatment dose, the endpoint techniqu e did so immediately.
The formul a for sublingual drop preparation is illu strated in table 3. Before preparation , one must know the volume (ml) requi red to deliver 100 drop s in the bottle of A suggested treatment schedule, as used in this office, is illustrated in table 4. This treatment schedule can vary according to the patient' s needs and clinical respon se. For exa mple, histamine injections have been given as frequently as every 4 hours when necessary to relieve acute pruritis due to seve re urtic aria. Compli cations are rare and usually limited to headache with overdose. Because histamine is a powerful gastric secretagogue, care should be exerci sed in patients with gastric distress. Histamine is contraindicated in patients with frank ulcer. Another contraindication is the concurrent use of a monoamine oxidase inhibitor, because histamine is metabolized in the body by the monoamine oxidase system. Moreover, because its action may be largely initiated through H 2 receptors, the absence of H, recept ors in the gut and lungs would seem to preclude its use for anaphylaxis in these location s.
Accor ding to anecdot al reports, other situations where low-dose histamine therapy may be useful include the care of allergy patients for whom specific allergy testing and treatment may be ill-advised, such as a patient who is taking a beta blocker, or for those who may be unable to present for therapy forwhateverreason.29Histamine therapy has also been used to treat physical sensitivities to temperature or barometric changes. Its usefulness for patients with tinnitus appears to be largely confined to those cases associated with vestibular or vascular disorders.
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In-office study
Thi s office conducted a retrospective study of 100 rando mly selected patients. As noted, low-dose histamine appeared to be very help ful in 70% of these patients and of at least some value to another 10% (table 5). Patients who did not impro ve within 2 months on this treatment program (20%) were decl ared treatment failures and were sw itched to a different therapy. Many of the successfully treated patients said they had been to many other physicians without experiencing any relief, despite the use of numerou s medication s. Several were skeptical about the effic acy of the low-dose appro ach befor e they agreed to undergo treatment. The response in some patients was dram atic.
In conclusion, low-dose histamine therapy for the appropr iate patient often significantly reduces morbidity, the need for othe r medi cations, and the overall cost of management.
